Regenerative medical devices group Tissue Regenix has been granted a Human Tissue Authority (HTA) licence to import and distribute its portfolio of human tissue derived products from the US for use in the UK market.
The HTA license will initially be used to import the CellRight ‘BioRinse’ portfolio of osteoinductive bone products from a manufacturing facility in San Antonio, Texas into the UK.
The group acquired CellRight in August last year, securing access to the US biotech’s osteoinductive and wound care scaffolds “that enhance healing opportunities of defects created by trauma and disease”.
“Receiving the HTA license is a pivotal milestone as we complete the integration of CellRight into the Group. This allows us to import the BioRinse portfolio in to the UK and ultimately, over time, distribute throughout Europe to meet increasing demand for our novel regenerative medicines,” said the AIM-listed firm’s chief executive Steve Couldwell.
“The HTA license provides the flexibility to import, store and distribute our portfolio of innovative products, a key commercial growth driver for the Group in the future.”
Tissue Regenix, which spun out of the University of Leeds in 2006, also announced that has also signed a three-year, non-exclusive UK distribution agreement with Pennine Healthcare “to drive commercial execution”.
Under the terms of the deal, Pennine will have access to the firm’s portfolio of novel bone and soft tissue products, which will complement its existing range of spinal implants.
